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Osteoma Cutis

Diana A. Rivers, DO and Cynthia Bartus, MD
Lehigh Valley Health Network, Allentown, Pa.

History of Present Illness: The patient presents with a five-year history of a
progressively worsening facial rash. The rash began with a few acneiform papules of
the left infraorbital skin and progressed to monomorphic, yellow papules of the
cheeks and chin. The patient was prescribed tretinoin 0.05% cream and discontinued
use due to irritation. The patient completed 10 microdermabrasion sessions with
minimal improvement.
Medical History/Surgical History: Acne, rosacea, keratoconjunctivitis sicca,
cheilitis, tonsillectomy
Medications: Hypromellose ophthalmic 0.3% gel, loteprednol etabonate ophthalmic
0.5% suspension, carmellose sodium 5 mg/glycerin 9 mg ophthalmic drops,
conjugated estrogens/medroxyprogesterone acetate, cyclosporine ophthalmic
emulsion 0.05% drops, polyethylene glycol 400-0.4%/propylene glycol 0.3%
ophthalmic solution, lifitegrast ophthalmic 5% solution, calcium-vitamin D,
evening primrose oil, vitamin E
Previous Treatments: Azelaic acid 15% gel, clindamycin/benzoyl peroxide 1.22.5% gel, metronidazole 1% gel, doxycycline 50 mg daily, tretinoin 0.05% cream
Current Treatment: Salicylic acid 2% wash
Physical Examination: Multiple, firm, 1-2 mm deep papules on cheeks and chin.
Central facial erythema.
Laboratory Data: CBC, CMP, calcium WNL. Antinuclear Ab screen negative.
Biopsy: Advanced Dermatology Associates, LTD (AD17-03168, 03/23/2017) Left
lateral cheek: “Well-defined focus of mature trabecular bone containing lacunae of
osteocytes with calcification situated within the dermis.”

Figure 1: Right cheek and mandible. Numerous, firm,
1-2 mm dermal papules.

Figure 2: Bilateral cheeks and Chin. Numerous, firm,
1-2 mm dermal papules.  
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Figure 3: H&E, Left cheek (10x): Well-defined focus of
mature trabecular bone containing lacunae of osteocytes
with calcification situated within the dermis.

Figure 4: H&E, Left cheek (10x): Decalcified, dermal
focus of mature trabecular bone containing lacunae
of osteocytes.
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Diagnosis: Osteoma Cutis
Osteoma cutis (OC) is a rare, benign condition of cutaneous bone formation and was
first described by Wilekens in 1858. A variant of osteoma cutis, known as multiple
miliary osteoma cutis (MMOC), was later described by Virchow in 1864. Primary OC
results from de novo bone formation in the skin while secondary OC occurs from
inflammatory, neoplastic, metabolic, traumatic, or iatrogenic causes. The MMOC
variant presents as several tiny cutaneous osteomas and includes both primary and
secondary forms of osteoma cutis. Syndromes associated with osteoma formation
include Albright’s hereditary osteodystrophy, fibrodysplasia ossificans progressiva,
progressive osseous heteroplasia, and plate-like osteoma cutis.
There are 102 reported cases in the literature to date of miliary osteoma cutis. A
female predilection exists, but hormones are not reported to have a pathogenic role in
the development of primary miliary osteoma cutis. Rarely, MMOC occurs as a delayed
sequelae in patients with a history of scarring acne vulgaris. Patients whose acne was
treated with minocycline or tetracycline can have osteomas with blue pigmentation.
The etiology of this condition remains unknown. The leading hypothesis suggests
osteoblastic metaplasia of mesenchymal cells (i.e. fibroblast metaplasia) giving rise to
these tumors. Clinically, the lesions are asymptomatic, firm, skin-colored to white,
dermal papules or nodules distributed on the scalp, face, trunk, buttocks, and
extremities. Osteomas can develop in acne lesions, nevi, scars, and sites of trauma.
Additionally, osteomas may arise in venous stasis dermatitis, collagen disease
(e.g. dermatomyositis, scleroderma), and neoplasms (e.g. pilomatricoma, basal
cell carcinoma).
Diagnosis is confirmed with the histopathologic finding of bony trabeculae. Serum
calcium levels, parathyroid levels, and screening for renal dysfunction should be
performed to exclude derangements in calcium metabolism. Treatment includes
medical management with topical tretinoin that may result in transepidermal
elimination of bone. However, surgical treatments provide the best results and include
punch excision, scalpel incisions with curettage, and microincision with extirpation.
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